Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont, Alexander M M

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. [electronic resource] - The New England journal of medicine May 2018 - 1789-1801 p. digital

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

1533-4406

10.1056/NEJMoa1802357 doi


Adjuvants, Immunologic--adverse effects
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized--adverse effects
B7-H1 Antigen--analysis
Disease-Free Survival
Double-Blind Method
Female
Humans
Infusions, Intravenous
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Melanoma--drug therapy
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Quality of Life
Skin Neoplasms--drug therapy
Survival Rate